Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes

Type 2 diabetes (T2DM) is closely associated with the development of heart failure, which might be related with impaired substrate metabolism and accumulation of myocardial lipids (MYCL). The aim of this study was to investigate the impact of an acute pharmacological inhibition of adipose tissue lipolysis leading to reduced availability of circulating FFA on MYCL and heart function in T2DM.
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - Category: Nutrition Authors: Source Type: research

Related Links:

Publication date: Available online 13 December 2019Source: Journal of Oral and Maxillofacial Surgery, Medicine, and PathologyAuthor(s): Jerónimo Lazos, Eugenia Rodríguez Marco, Mabel Brunotto, Rene Panico, Eduardo PiemonteAbstractObjectiveOral venous varicosities (OV) are a common condition, increasing its incidence with age. They are also mentioned in association with several medical conditions, but the evidence is scarce and inconsistent. The aim was to describe OV clinical features and to analyze the association with medical conditions.MethodsAn observational, cross-sectional study was carried out in the O...
Source: Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology - Category: ENT & OMF Source Type: research
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractAdults with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in adults with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other phase 3 cl...
Source: Canadian Journal of Diabetes - Category: Endocrinology Source Type: research
Prevalence set to soar by 40% among older people in eight major country markets, including the UK, forecast suggests Related items fromOnMedica Coronary heart disease remains UK ’s biggest killer Women less likely than men to achieve CHD targets Type 2 diabetes in 10 times more young people than realised NICE says far more people should take statins Apply different obesity criteria to BME patients
Source: OnMedica Latest News - Category: UK Health Source Type: news
CONCLUSIONS: Pioglitazone should be considered in patients with or at high risk of T2DM for the prevention of cardiovascular endpoints, especially in those with a history of established CVD who might benefit the most. Robust reductions in progression of renal disease are seen regardless of baseline renal function degree. PMID: 31822895 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
AimsImpact of type 2 diabetes mellitus (T2DM) on non ‐thromboembolic outcomes in atrial fibrillation (AF) is insufficiently explored. This prospective cohort study of AF patients aimed (i) to analyse the association between T2DM and heart failure (HF) events (including new‐onset HF), and all‐cause and cardiovascular mortality, (ii) to assess the impact of baseline T2DM treatment on outcomes, and (iii) to explore characteristics of new‐onset HF phenotypes in relation to T2DM status.Methods and resultsOf 1803 AF patients (515/1288, with/without prior HF), 389 (22%) had T2DM at baseline. After 5  years of media...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
ConclusionsIn patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF ‐related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
European Journal of Heart Failure, EarlyView.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Editorial Comment Source Type: research
ABSTRACTType 2 diabetes mellitus (T2DM) is common in patients with heart failure (HF) and associated with considerable morbidity and mortality. Significant advances have recently occurred in the treatment of T2DM, with evidence of several new glucose ‐lowering medications showing either neutral or beneficial cardiovascular effects. However, some of these agents have safety characteristics with strong practical implications in HF [i.e. dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA), and sodium–glucose co‐transporter type 2 (SGLT‐2) inhibitors].Regarding ...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Position Paper Source Type: research
ConclusionsIn patients with type 2 diabetes mellitus and established CV disease, those with AF at baseline had higher rates of adverse HF outcomes than those without AF. Irrespective of the presence of AF, empagliflozin reduced HF ‐related and renal events. The absolute number of prevented events is higher in patients with AF than without AF. Patients with diabetes, CV disease and AF may especially benefit from use of empagliflozin.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Research Article Source Type: research
European Journal of Heart Failure, EarlyView.
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Editorial Comment Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Heart Failure | Nutrition | Study